NRX Pharmaceuticals Inks Data Sharing Agreement Demonstrating Efficacy And Safety Of Intravenous Ketamine For Suicidal Bipolar Depression Treatment, Plans To Present Data To FDA With Goal Of Identifying A Path To An NDA
Portfolio Pulse from Benzinga Newsdesk
NRX Pharmaceuticals has signed a data sharing agreement that demonstrates the efficacy and safety of intravenous ketamine for treating suicidal bipolar depression. The company plans to present this data to the FDA with the aim of identifying a path to a New Drug Application (NDA).
September 15, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The data sharing agreement signed by NRX Pharmaceuticals could potentially lead to a New Drug Application for their intravenous ketamine treatment for suicidal bipolar depression. This could have a positive impact on the company's stock.
The news of a potential new drug application is generally seen as positive for pharmaceutical companies as it could lead to new revenue streams. The fact that NRX Pharmaceuticals is planning to present this data to the FDA indicates that they are confident in the efficacy and safety of their treatment, which could also be seen as a positive sign by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100